Understanding the role of beta-1,6-glucan in the cell wall of a harmful fungus
Solving the puzzle of beta-1,6-glucan in the cryptococcal cell wall
This study is looking at a part of a fungus called Cryptococcus neoformans that can be harmful to people with weakened immune systems, like those with HIV, to find ways to make better treatments for infections caused by it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11209714 on NIH RePORTER |
What this research studies
This research investigates the cell wall of Cryptococcus neoformans, a fungus that poses a significant health risk, particularly to individuals with weakened immune systems, such as those living with HIV. The focus is on understanding beta-1,6-glucan, a crucial component of the cell wall that helps maintain its structure and integrity. By exploring how this glucan is synthesized, the research aims to identify potential vulnerabilities that could be targeted by antifungal therapies. This could lead to the development of more effective treatments for infections caused by this pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with compromised immune systems, particularly those living with HIV or other conditions that increase susceptibility to fungal infections.
Not a fit: Patients who are not immunocompromised or do not have a history of Cryptococcus neoformans infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antifungal therapies that are effective against Cryptococcus neoformans infections.
How similar studies have performed: Previous research has shown success in targeting fungal cell wall components for antifungal therapy, indicating that this approach has potential.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Doering, Tamara L — Washington University
- Study coordinator: Doering, Tamara L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.